Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham’s Virtual Neuroscience Forum and provide a commercial update of BIIB‘s Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY‘s donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
- Needham healthcare analyst to hold an analyst/industry conference call
- Biogen Appoints Chuck Triano as Head of Investor Relations
- Biogen appoints Triano as Head of Investor Relations
- Biogen ‘welcomes’ VHA recent decision to provide coverage to Leqembi